Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Navio MD vs Nucific

Navio MD
Graded #126

Higher grade

vs+13.299999999999997
Nucific
Graded #418

Lower grade

The verdict

Navio MD takes it — 69.5/100 to 56.2/100.

Navio MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NavioMD offers compounded tirzepatide ($247/mo) plus brand-name Ozempic ($1,199/mo) and Mounjaro ($1,249/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNavio MD +11
56
45
Dose & formulationNavio MD +24
77
53
Clinical oversightNavio MD +11
87
76
Labs & monitoringNavio MD +2
54
52
FulfillmentNavio MD +18
85
67
Contract termsNavio MD +14
55
41
Navio MD · left barNucific · right bar

The numbers

MetricNavio MDNucific
WeighScore69.5/10056.2/100
GradeCC
Scorecard rank#126#418
Semaglutide$345/mo (starting dose, brand-name)Not disclosed
Tirzepatide$189/mo (starting dose, compounded)Not disclosed
Coverage48 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Navio MD

Graded #126 · C

Strengths

  • LegitScript verified with board-certified providers and US-licensed pharmacies
  • Both compounded and brand-name options
  • 48-state coverage
  • Hours 9am–10pm EST Mon–Sun
  • Transparent tiered pricing: you only pay for your current dose

Where it loses points

  • Not available in Alabama and Mississippi
  • Compounded option is tirzepatide only — no compounded semaglutide listed
  • Also offers women's HRT (broader platform)
  • Pricing is tiered by dose ('as low as'); the entry prices climb as your dose increases
Nucific

Graded #418 · C

Strengths

  • Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
  • Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
  • Discloses that featured patients were compensated for their time
  • Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
  • Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue

Where it loses points

  • No price is published anywhere; every option is gated behind a three-minute quiz
  • The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
  • A BBB Accredited A+ claim is displayed without a link to the BBB profile
  • No state list and no named pharmacy, only licensed U.S. pharmacies
  • Before-and-after photographs are used alongside compensated testimonials

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard